News Release - Nov 16, 2022 - BioHarvest Sciences signs first US agreement with Royal Emerald Pharmaceuticals to Supply Disruptive Cannabis Solutions to Companies Conducting FDA-Approved Medical Research. Read full release ​

June 2024

BioHarvest Sciences Announces Closing of USD $4,329,982 in First Tranche of Private Placement and Conversion of Debt Notes

Vancouver, British Columbia and Rehovot, Israel – June 28, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCD) has closed the first tranche of its private placement announced on June 21, 2024. The Company issued 603,904 share units at USD $7.17 per unit raising a total of USD $4,329,982.62 (approx. CAD $5,926,000). […]

BioHarvest Sciences Announces Closing of USD $4,329,982 in First Tranche of Private Placement and Conversion of Debt Notes Read More »

BioHarvest Sciences to Present at Noble Capital Markets Virtual Equity Conference on June 27, 2024

Vancouver, British Columbia and Rehovot, Israel – June 24, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCD), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will present at the Noble Capital Markets Virtual Equity Conference, being held June 26-27, 2024. CEO Ilan Sobel is scheduled to

BioHarvest Sciences to Present at Noble Capital Markets Virtual Equity Conference on June 27, 2024 Read More »

BioHarvest Sciences Announces a Private Placement of up to USD $5 Million and Conversion of Debt Notes

Vancouver, British Columbia and Rehovot, Israel – June 21, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCD), announced today that its board of directors have approved a private placement of up to 697,350 units at a price of USD $7.17 per unit (approx. CAD $9.82) for gross proceeds of up to

BioHarvest Sciences Announces a Private Placement of up to USD $5 Million and Conversion of Debt Notes Read More »

BioHarvest Sciences to Present at Sidoti Small-Cap Virtual Investor Conference on June 13, 2024

Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – June 12, 2024) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to present at the Sidoti Small-Cap Investor Conference, being held June 12-13, 2024. CEO Ilan Sobel is scheduled

BioHarvest Sciences to Present at Sidoti Small-Cap Virtual Investor Conference on June 13, 2024 Read More »

The Biotech Journey

BioHarvest Sciences Announces Record $2 Million Monthly Sales

VINIA® Subscription Growth Drives 101% Year-over-Year Increase in May Product Sales Orders; Cumulative Customer Reviews Surpass 5,000 Vancouver, British Columbia and Rehovot, Israel – June 6, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCD), a company pioneering its patented Botanical Synthesis technology platform, today announced that VINIA®, the first commercialized product

BioHarvest Sciences Announces Record $2 Million Monthly Sales Read More »

BIOHARVEST SCIENCES INC. ANNOUNCES COMPLETION OF CONSOLIDATION

VANCOUVER, CANADA, and REHOVOT, ISRAEL, June 3, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) announces the completion of the consolidation (the “Consolidation”) of all of its issued and outstanding common shares (“Common Shares”) on the basis of thirty-five (35) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share. Immediately upon

BIOHARVEST SCIENCES INC. ANNOUNCES COMPLETION OF CONSOLIDATION Read More »